Spiro Gavaris is the president, specialty generics at Mallinckrodt Pharmaceuticals. He has responsibility for the company’s specialty generics, active pharmaceutical ingredients and non-promoted brands products, and is a member of Mallinckrodt’s senior leadership team.
Mr. Gavaris has nearly 20 years of experience in pharmaceuticals and healthcare-related strategy, sales, marketing, operations, business development, integration, and life cycle management.
Previously Mr. Gavaris served as president of the U.S. Injectables division of Hikma, with prior roles including commercial leadership of its oral generics business unit and the launch and oversight of its U.S. brands division. Mr. Gavaris also served as a practice executive at Campbell Alliance consulting firm, working with pharmaceutical, biotech, animal health and device companies to enhance their commercial strategy and operations. He entered the pharmaceuticals industry in sales for Bristol Myers-Squib after working as a civil engineer.
Mr. Gavaris holds a bachelor’s degree from Franklin and Marshall College and an MBA in marketing and management from New York University, Stern School of Business.